Approved IND applications for topical ophthalmic, intraocular/intravitreal sustained release drugs and combination drug/device products:

  • Topical ophthalmic drugs and biologics for corneal wound-healing (growth factors), glaucoma (NCE), keratoconjunctivitis sicca (NCE, 505(b)2)
  • Short-interfering RNA (siRNA) for AMD and DME products
  • Sustained release intraocular dexamethasone drug delivery systems for diabetic patients
  • Light-activated drug product
  • Intraocular implant of ganciclovir in cytomegalovirus retinitis
  • Chondroitin sulfate-enhanced intraocular irrigating solution
  • Recombinant human epidermal growth factor in multiple ophthalmic indications (corneal wound healing, endothelial protection)
  • Long-acting intraocular steroid for DME, BRVO, CRVO and CME
  • Latanoprost sustained release formulations for Glaucoma
  • Drug delivery system for combination prostate therapeutic combination product
  • Intraductal chemotherapeutic agent for breast cancer
  • Immunomodulator in treatment of AIDS-related Complex (ARC)
  • Smoking cessation drug
  • Pirenzipene for myopia prevention
  • Cyclosporine for keratoconjunctivitis sicca